MGX
Metagenomi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.81
+3.55%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.81
From 52W high−75.77%
Volume154483.00
Market cap$30.67M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataOct 19, 2026
Open
$0.81
From 52W high
−75.77%
Volume
154483.00
Market cap
$30.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
24.8
MomentumView details →
1D Return
+3.55%
YTD Return
−49.92%
SummaryUpdated Jun 1, 2026
Metagenomi, Inc. (NASDAQ:MGX) is a gene editing biotechnology company founded in 2016 and headquartered in Emeryville, California. The company went public in 2006 and focuses on developing therapeutic treatments using advanced genome editing technologies derived from metagenomics research. Metagenomi has established strategic partnerships with major pharmaceutical companies including Moderna, Affini-T Therapeutics, and Ionis Pharmaceuticals to advance its gene editing platform for various therapeutic applications.
Similar companies
Latest newsMore news →
Metagenomi Therapeutics reported a Q2 2026 loss of $0.73 per share, missing the Zacks Consensus Estimate of a $0.63 loss and wider than the year-ago loss of $0.54 per share.70d agoBrian C. Thomas, Ph.D. resigned as a member of the Board of Metagenomi Therapeutics, Inc., effective June 9, 2026.132d ago